2022
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Ventura-Cots M, Argemi J, Jones PD, Lackner C, Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carrillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, Straub BK, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut 2022, 71: 1856-1866. PMID: 34992134, PMCID: PMC11034788, DOI: 10.1136/gutjnl-2021-324295.Peer-Reviewed Original ResearchConceptsAlcohol-related liver diseaseAlcohol-related hepatitisAH patientsLiver diseaseAlcohol intakeDuctular reactionGamma-glutamyl transferase levelsProfound liver failureSevere neutrophil infiltrationWorse liver functionObservational multicentre studyOne-year mortalityBile acid metabolismMallory-Denk bodiesRNA microarray analysisNeutrophil infiltrationProspective cohortRetrospective cohortAdvanced fibrosisLiver failureMulticentre studySteatosis gradeLiver functionPericellular fibrosisSevere fibrosis
2020
Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis
Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Lucey MR, Louvet A, Mathurin P, Garcia‐Tsao G, Ho SB, Tu XM, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology 2020, 71: 522-538. PMID: 31228214, PMCID: PMC6925657, DOI: 10.1002/hep.30832.Peer-Reviewed Original ResearchConceptsAnti-Saccharomyces cerevisiae antibodiesSerum anti-Saccharomyces cerevisiae antibodiesAlcoholic hepatitisSystemic immune responsesAlcohol use disorderASCA levelsLiver diseaseNonalcoholic controlsImmune responseUse disordersAlcohol-associated liver diseaseAlcohol-related liver diseaseHigher ASCA levelsIntestinal Fungal DysbiosisOvergrowth of CandidaAdjusted hazard ratioCohort of patientsChronic alcohol consumptionIntestinal microbiota compositionIU/mLCerevisiae antibodiesFecal mycobiotaHepatitis cohortHazard ratioSteroid treatment